# US 2026/0061118 A1 · Basal bolus treatment devices and methods > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0061118 A1 - Document ID: US20260061118A1 - Status: Published application - Kind: A1 - Application number: 19/309,936 - Filed: 2025-08-26 - Published: 2026-03-05 - Earliest claimed: 2024-08-27 - Applicants: Quasuras, Inc. - Inventors: Paul M. DIPERNA; James BESSER; Stephen DALY; David MAGGS - Web page: https://patentgrep.com/patent/US20260061118A1 ## CPC - A61M 5/142: Pressure infusion, e.g. using pumps - A61M 5/14244: {adapted to be carried by the patient, e.g. portable on the body} - A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure} - A61M 2005/14208: {with a programmable infusion control system, characterised by the infusion program} - A61M 2205/3303: Using a biosensor - A61M 2205/502: User interfaces, e.g. screens or keyboards - A61M 2230/005: Parameter used as control input for the apparatus - A61M 2230/201: Glucose concentration - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} ## Abstract A drug delivery system for administering a GLP-1 agonist therapy includes a reservoir configured to contain a GLP-1 agonist, a pump in fluid communication with the reservoir and configured to deliver the GLP-1 agonist, a controller operatively coupled to the pump, and a user interface operatively coupled to the controller. The controller is programmed to deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. The system allows for independent adjustment of basal and bolus doses based on patient-specific parameters, enabling personalized GLP-1 agonist therapy administration. ## Claims ### Claim 1 A drug delivery system for administering a GLP-1 agonist therapy, comprising: a reservoir configured to contain a GLP-1 agonist; a pump in fluid communication with the reservoir and configured to deliver a GLP-1 agonist; a controller operatively coupled to the pump; and a user interface operatively coupled to the controller, wherein the controller is programmed to: deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period; and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. ### Claim 2 (depends on 1) The drug delivery system of claim 1, wherein the basal dose and the at least one bolus dose are independently adjustable. ### Claim 3 (depends on 1) The drug delivery system of claim 1, wherein the controller is further programmed to adjust the basal dose and the at least one bolus dose based on patient-specific parameters. ### Claim 4 (depends on 3) The drug delivery system of claim 3, wherein the patient-specific parameters include at least one of body weight, meal size, time of day, or glucose levels. ### Claim 5 (depends on 1) The drug delivery system of claim 1, wherein the controller is programmed to deliver multiple bolus doses at different times within a 24-hour period. ### Claim 6 (depends on 1) The drug delivery system of claim 1, wherein the basal dose comprises 10% to 90% of a total daily dose of the GLP-1 agonist. ### Claim 7 (depends on 1) The drug delivery system of claim 1, further comprising a reservoir containing the GLP-1 agonist, wherein the GLP-1 agonist is a short-acting GLP-1 receptor agonist. ### Claim 8 (depends on 1) The drug delivery system of claim 1, wherein the user interface is configured to receive user input for adjusting the basal dose and the at least one bolus dose. ### Claim 9 (depends on 1) The drug delivery system of claim 1, further comprising a glucose sensor operatively coupled to the controller, wherein the controller is programmed to adjust the basal dose and the at least one bolus dose based on glucose readings from the glucose sensor. ### Claim 10 (depends on 1) The drug delivery system of claim 1, wherein the controller is programmed to deliver the at least one bolus dose in response to a meal-related input received through the user interface. ### Claim 11 A method of administering a GLP-1 agonist therapy, comprising: delivering a basal dose of a GLP-1 agonist continuously over a 24-hour period using a pump; and delivering at least one bolus dose of the GLP-1 agonist in addition to the basal dose using the pump. ### Claim 12 (depends on 11) The method of claim 11, further comprising: independently adjusting the basal dose and the at least one bolus dose. ### Claim 13 (depends on 11) The method of claim 11, further comprising adjusting the basal dose and the at least one bolus dose based on patient-specific parameters. ### Claim 14 (depends on 13) The method of claim 13, wherein the patient-specific parameters include at least one of body weight, meal size, time of day, or glucose levels. ### Claim 15 (depends on 11) The method of claim 11, wherein delivering the at least one bolus dose comprises delivering multiple bolus doses at different times within the 24-hour period. ### Claim 16 (depends on 11) The method of claim 11, wherein the basal dose comprises 10% to 90% of a total daily dose of the GLP-1 agonist. ### Claim 17 (depends on 11) The method of claim 11, wherein the GLP-1 agonist is a short-acting GLP-1 receptor agonist. ### Claim 18 (depends on 11) The method of claim 11, further comprising receiving user input through a user interface for adjusting the basal dose and the at least one bolus dose. ### Claim 19 (depends on 11) The method of claim 11, further comprising: adjusting the basal dose and the at least one bolus dose based on glucose readings from a glucose sensor operatively coupled to the pump. ### Claim 20 (depends on 11) The method of claim 11, wherein delivering the at least one bolus dose comprises delivering the bolus dose in response to a meal-related input received through a user interface.